NASDAQ:MBRX
Moleculin Biotech Inc Stock News
$4.76
-0.0200 (-0.418%)
At Close: May 10, 2024
Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference
08:40am, Thursday, 20'th Jan 2022
HOUSTON, Jan. 20, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
Moleculin to Present at the H.C. Wainwright BioConnect Conference
08:30am, Friday, 07'th Jan 2022
HOUSTON, Jan. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti
Moleculin Biotech Inc Shares Fall 6.8% Below Previous 52-Week Low - Market Mover
01:10am, Thursday, 30'th Dec 2021 Kwhen Finance
Moleculin Biotech Inc (MBRX) shares closed 6.8% lower than its previous 52 week low, giving the company a market cap of $50M. The stock is currently down 93.8% year-to-date, down 94.5% over the past 12 months, and down 97.9% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 41.9% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 815.3% The company's stock price performance over the past 12 months lags the peer average by 877.7%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
State Street Corp Purchases New Holdings in Moleculin Biotech, Inc. (NASDAQ:MBRX)
09:14am, Friday, 10'th Dec 2021 Dakota Financial News
State Street Corp purchased a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 59,900 shares of the companys stock, valued at approximately $220,000. State Street Corp owned about 0.21% of Moleculin []
Read Why Is Roth Capital Bullish On This Cancer-Focused Stock
02:08pm, Wednesday, 01'st Dec 2021
Roth Capital notes that the FDA cleared Moleculin Biotech Inc's (NASDAQ:MBRX) WP1122 to start a Phase 1 trial in glioblastoma multiforme, which will be in addition to the drug's impending parallel
Moleculin Biotech (NASDAQ:MBRX) Cut to Hold at Zacks Investment Research
10:34am, Thursday, 18'th Nov 2021 Dakota Financial News
Zacks Investment Research cut shares of Moleculin Biotech (NASDAQ:MBRX) from a buy rating to a hold rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The companys lead product candidate is Annamycin, []
Moleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event
08:05am, Friday, 12'th Nov 2021
HOUSTON, Nov. 12, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
MBRX Stock: Why It Increased Today
03:54pm, Tuesday, 19'th Oct 2021
The stock price of Moleculin Biotech Inc (NASDAQ: MBRX) increased by over 2% during intraday trading today. This is why it happened.
HOUSTON, Oct. 19, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting
HOUSTON, Oct. 18, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targ
Moleculin to Present at the 2021 Cantor Virtual Global Healthcare Conference
07:05am, Monday, 27'th Sep 2021
HOUSTON, Sept. 27, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting
Moleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
08:05am, Friday, 17'th Sep 2021
HOUSTON, Sept. 17, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting
Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update
08:18am, Thursday, 12'th Aug 2021
HOUSTON, Aug. 12, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
HOUSTON, July 13, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates target
HOUSTON, June 21, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targ